The Ensign Group, Inc. (ENSG) Stock Price & How to Invest

The Ensign Group runs a network of independently operated skilled nursing facilities, senior living communities, and rehabilitation services across the United States, plus a growing real estate arm (Standard Bearer). As of mid-2026 its subsidiaries operated roughly 398 healthcare operations, including about 48 senior living communities, across 17 states, with a real estate portfolio of roughly 183 properties. The business model is to acquire underperforming but strategically located facilities and turn them into profitable local operations, generating revenue mostly from Medicare, Medicaid, and private-insurance reimbursement for short-term rehab and long-term care.

The investment picture centers on durable, acquisition-fueled growth. Ensign has delivered years of double-digit revenue and earnings gains by improving occupancy, skilled mix, and staff retention at newly acquired sites while keeping a strong balance sheet. In Q1 2026 revenue rose about 18% to roughly $1.39 billion and adjusted EPS grew more than 20%, prompting management to raise full-year guidance. The trade-off is a premium valuation and heavy dependence on government reimbursement rates and labor costs, which makes execution and policy the key variables rather than demand, since an aging population supplies a long structural tailwind.

Ensign derives the majority of its revenue from Medicare and Medicaid, so any cut, freeze, or unfavorable change to government reimbursement rates would pressure margins directly. The skilled nursing industry is labor-intensive and exposed to persistent workforce shortages and wage inflation, and proposed federal minimum-staffing mandates could raise costs if reinstated. Growth depends on continuously finding and integrating acquisitions at attractive prices, so a slower pipeline or integration missteps would slow the compounding. The stock also trades at a premium valuation, which leaves less cushion if growth decelerates. Finally, the sector carries regulatory, litigation, and quality-of-care compliance risk that can produce fines or reputational damage.

5 analysts publish price targets on ENSG, averaging $220.00 against a $178.16 price as of August 2026, or +23.5%. The published targets run from $207.00 to $230.00, a narrow spread, and the ratings split 4 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ENSG forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on The Ensign Group, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Serial-acquisition growth engine. Ensign's core strategy is buying underperforming skilled nursing and senior living facilities and improving their operations. The most optimistic published target, $230.00, assumes this works close to its best case.

The case against. Ensign derives the majority of its revenue from Medicare and Medicaid, so any cut, freeze, or unfavorable change to government reimbursement rates would pressure margins directly. The most pessimistic target, $207.00, is roughly what ENSG is worth if this bites instead.

Read the full bull and bear case on ENSG, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see The Ensign Group, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$5.3B
• 2026 revenue guidance: ~$5.81B to $5.86B
• 2026 EPS guidance (diluted): ~$7.48 to $7.62
• Market cap: ~$9.9B
• Trailing P/E: ~27x
• Forward P/E: ~20x

Ensign trades at a premium to typical healthcare-facility peers, reflecting its consistent double-digit growth and strong balance sheet (roughly $540 million cash against about $143 million of debt in early 2026). Q1 2026 revenue grew about 18% year over year to roughly $1.39 billion with adjusted EPS up more than 20%, and management raised full-year guidance. The premium multiple assumes the acquisition-led growth continues.

If you want ENSG exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to ENSG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ENSG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (IJR), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ENSG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ENSG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Ensign is a rare skilled-nursing operator that keeps compounding revenue and earnings at double-digit rates, and the market prices it accordingly.

Whether ENSG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ENSG a buy or a sell?, and where the stock could go from here in the ENSG stock forecast.

For income investors, whether ENSG pays a dividend and how the payout looks is covered in does ENSG pay a dividend? And to weigh ENSG against a peer, read the full side-by-side comparisons: ENSG vs NHC and ENSG vs GEL.